Compare Adaptive Biotechnologies Corp (ADPT) vs Verizon Communications Inc (VZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Verizon Communications Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Verizon Communications Inc trades at $42.66 (market cap $177.84B). The key difference: Verizon Communications Inc is far larger — about 53.4× Adaptive Biotechnologies Corp's market cap, and Verizon Communications Inc pays a 6.64% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | VZ | |
|---|---|---|
Market Cap | $3.33B | $177.84B |
Sector | Health | Media |
52-Week High | $22.37 | $51.38 |
52-Week Low | $10.24 | $38.40 |
Enterprise Value | $3.19B | $365.34B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
